biostudies-literatureKuang Zthe National Key Research and Development Program of China939-950https://www.ebi.ac.uk/biostudies/studies/S-EPMC11027608biostudies-literatureUnknown69(6)With the great success of anti-CTLA-4 and anti-PD-1 therapeutics in cancer immunotherapy, tumor necrosis factor receptor superfamily members have been recognized as ideal targets to provide co-stimulatory signals in combination with immune checkpoint blocking antibodies. Among these is OX40 (CD134), a co-stimulatory molecule expressed by activated immune cells. Recently, several anti-OX40 agonistic monoclonal antibodies, pogalizumab as the most advanced, have entered early phase clinical trials. Using a yeast platform and multiple screening methods, we identified a fully human anti-OX40 antibody (IBI101) with distinct modes of action. Unlike pogalizumab, IBI101 partially blocks the binding of OX40 to its ligand OX40L and exhibits both FcγR-dependent and independent agonistic activities in Cancer immunology, immunotherapy : CIIDevelopment and characterization of a novel anti-OX40 antibody for potent immune activation.PMC110276082017YFC0909801Jing HBaruah HWu MLiu JPrinz BYu MNi HZhou SWu DWang JChen BKuang ZZhang PWu ZLi YQiu XWu WfalseDevelopment and characterization of a novel anti-OX40 antibody for potent immune activation.With the great success of anti-CTLA-4 and anti-PD-1 therapeutics in cancer immunotherapy, tumor necrosis factor receptor superfamily members have been recognized as ideal targets to provide co-stimulatory signals in combination with immune checkpoint blocking antibodies. Among these is OX40 (CD134), a co-stimulatory molecule expressed by activated immune cells. Recently, several anti-OX40 agonistic monoclonal antibodies, pogalizumab as the most advanced, have entered early phase clinical trials. Using a yeast platform and multiple screening methods, we identified a fully human anti-OX40 antibody (IBI101) with distinct modes of action. Unlike pogalizumab, IBI101 partially blocks the binding of OX40 to its ligand OX40L and exhibits both FcγR-dependent and independent agonistic activities in 2020-01-01T00:00:00Z2020 Jun2025-04-22T20:45:52.187Z2025-04-06T03:15:03.373ZS-EPMC110276083207801510.1007/s00262-020-02501-2